Table 3.
Retinopathy of prematurity severity in neonates requiring treatment across all time periodsa
| Study parameter | All time periods Nb = 144 |
Time period 1c n = 23b | Time period 2 n = 41b | Time period 3 n = 44b | Time period 4 n = 36b | P valued |
|---|---|---|---|---|---|---|
| Zone of ROP at treatment, no. (%) | ||||||
| 1 | 27 (18.8) | 1 (4.4) | 14 (34.1) | 7 (15.0) | 5 (13.9) | 0.03 |
| 2 | 95 (66.0) | 19 (82.6) | 21 (51.2) | 27 (61.4) | 28 (77.8) | |
| 3 | 13 (9.0) | 3 (13.0) | 2 (4.9) | 6 (13.6) | 2 (5.6) | |
| Not reported | 9 (6.3) | 0 | 4 (9.8) | 4 (9.1) | 1 (2.8) | |
| Stage of ROP at treatment, no. (%) | ||||||
| 1 | 7 (4.9) | 1 (4.3) | 2 (4.9) | 2 (4.5) | 2 (5.6) | 0.63 |
| 2 | 19 (13.2) | 3 (13.0) | 2 (4.9) | 7 (15.0) | 7 (19.4) | |
| 3 | 99 (68.8) | 14 (60.9) | 33 (80.5) | 28 (63.6) | 24 (66.7) | |
| 4 | 2 (1.4) | 1 (4.3 | 0 (0) | 0 (0) | 1 (2.8) | |
| 5 | 1 (0.7) | 0 (0) | 1 (2.4) | 0 (0) | 0 (0) | |
| Not reported | 16 (11.1) | |||||
| AROP, no. (%) | 36 (25) | 0 (0) | 19 (46.3) | 8 (18.2) | 9 (25.0) | <0.01e |
| Plus disease, no. (%) | 98 (68.1) | 12 (52.2) | 32 (78.1) | 22 (50.0) | 32 (88.9) | 0.01f |
AROP, aggressive retinopathy of prematurity; ROP, retinopathy of prematurity.
a
Time periods: (1) November 1, 2018, to March 15, 2019; (2) March 16, 2019, to August 2, 2019; (3) November 1, 2019, to March 15, 2020; (4) March 16, 2020, to August 2, 2020 (lockdown period).
b
Number of patients
c
Data available for 4/7 institutions.
d
A P value of ≤0.05 was considered significant.
e
Significant difference between time period 1 and 2 (P < 0.01), 1 and 3 (P = 0.02), and 1 and 4 (P < 0.01)
f
Significant difference between time period 1 and 2 (P = 0.03), 1 and 4 (P < 0.01), 2 and 3 (P = 0.02), and 3 and 4 (P < 0.01).